Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow Quality Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow Quality Index of 4.85x as of September 2025. Operating cash flow of CN¥11.57 Million exceeds net income of CN¥2.39 Million, indicating high earnings quality where cash backs reported profits. Explore Hubei Biocause Heilen Pharmaceutical Co. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Hubei Biocause Heilen Pharmaceutical Co. (301211) cash conversion ratio.
Annual Cash Flow Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Year-by-year earnings quality comparison for Hubei Biocause Heilen Pharmaceutical Co. Ltd..
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥7.55 Million | CN¥34.91 Million | ▼ -79.4% |
| 2024 | 1.05x | CN¥96.07 Million | CN¥91.55 Million | ▲ +34.8% |
| 2023 | 0.78x | CN¥137.06 Million | CN¥176.12 Million | ▼ -61.0% |
| 2022 | 1.99x | CN¥250.79 Million | CN¥125.72 Million | ▲ +95.7% |
| 2021 | 1.02x | CN¥123.98 Million | CN¥121.65 Million | ▲ +40.8% |
| 2020 | 0.72x | CN¥121.67 Million | CN¥168.07 Million | ▼ -64.1% |
| 2019 | 2.02x | CN¥372.33 Million | CN¥184.62 Million | ▲ +142.2% |
| 2018 | 0.83x | CN¥76.18 Million | CN¥91.48 Million | ▲ +130.3% |
| 2017 | -2.75x | CN¥-65.44 Million | CN¥23.77 Million | — |